Home › Uveal Melanoma › Florida
Uveal Melanoma clinical trials in Florida
8 studies for Uveal Melanoma are looking for participants at sites in Florida.
Cities in Florida
Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
- Moffitt Cancer Center, Tampa
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 26, 2026 · NCT06961357Adjuvant Quisinostat in High-Risk Uveal Melanoma
- University of Miami, Miami
RecruitingPhase 2
Ages 19 and older · All sexes · Updated Jun 18, 2026 · NCT06932757ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- University of Miami Hospital and Clinics, Miami
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated May 13, 2026 · NCT03686124Neoadjuvant Darovasertib in Primary Uveal Melanoma
- Mayo Clinic Jacksonville, Jacksonville
- USF Health Eye Institute, Tampa
- Moffit Cancer Center, Tampa
RecruitingPhase 3
Ages 18 and older · All sexes · Updated May 6, 2026 · NCT07015190A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- Mayo Clinic - Jacksonville FL, Jacksonville
- Sylvester Comprehensive Cancer Center, Miami
RecruitingPhase 2/3
All ages · All sexes · Updated Apr 2, 2026 · NCT06581406Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
- Moffitt Cancer Center, Tampa
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Mar 31, 2026 · NCT07276386Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
- University of Miami, Miami
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 23, 2026 · NCT06627244Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
- Moffitt Cancer Center, Tampa
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Dec 4, 2025 · NCT06121180From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.